Findings Published in International Oncology
Journal
FORT
MYERS, Fla., May 7, 2024
/PRNewswire/ -- Florida Cancer Specialists & Research
Institute, LLC (FCS) medical oncologist and hematologist Mahdi
Taha, DO, FACOI, FACP is lead author and Kayla Haines, APRN is co-author of a case study
published in JCO® Precision Oncology detailing the importance of
genomic testing in identifying cancer and guiding targeted
treatment decisions that enhance overall survival, with a focus on
metastatic prostate cancer.
Inherited genetic mutations are known to increase risk for many
forms of cancer in women and men. Specifically, mutations in the
breast cancer genes (known as BRCA1 and BRCA2) are the cause of
aggressive forms of prostate cancer, the second most common cancer
diagnosed in American men.
In the article entitled, "Next-Generation Sequencing Testing Can
Save Generations of Lives," the authors note: "BRCA2 mutation
positive men are estimated to have an 8.6-fold increase in risk by
the age of 65 with an absolute risk of about 15% by the age of 65."
These cancers tend to be aggressive and can present earlier than
non-BRCA mutated cancers.
Dr. Taha said, "Our research shows that the identification of
these genetic factors, even in geriatric patients, is important for
determining targeted treatment and overall patient survival."
The article details the case of an 85-year-old male patient who
presented to FCS for evaluation and treatment for metastatic
prostate cancer with a rising PSA. Next-generation sequencing (NGS)
testing revealed a BRC2 mutation. "This finding was both crucial to
determine the treatment plan and also to inform potential
implications to the patient's family members."
It was later discovered that the patient's daughter had never
completed proper breast cancer screening. Following a subsequent
mammogram, she was diagnosed with breast cancer and treatment was
promptly started. "Had genomic testing never been done on our
patient, the BRCA2 mutation would have been unknown to the
daughter," added Dr. Taha.
FCS offers NGS testing at its clinics statewide to detect
oncogenic mutations in hundreds of different genes simultaneously,
enabling clinicians to make faster diagnoses of a wide range of
cancers while providing recommendations for clinical trials options
and personalized therapies based on each patient's results.
To access the study in JCO® Precision Oncology:
https://ascopubs.org/doi/10.1200/PO.23.00695
About Florida Cancer Specialists & Research Institute,
LLC: (FLCancer.com)
Florida Cancer Specialists &
Research Institute (FCS) offers patients access to more clinical
trials than any private oncology practice in Florida. The majority of new cancer drugs
recently approved for use in the U.S. were studied in clinical
trials with FCS participation.* Recognized for our research, FCS is
a recipient of the national Clinical Trials Participation Award
presented by the American Society of Clinical Oncology (ASCO). FCS
physicians, trained in prestigious medical schools and research
institutes, are consistently ranked nationally as Top Doctors by
U.S. News & World Report.
Founded in 1984, FCS has built a national reputation for
excellence that is reflected in exceptional and compassionate
patient care, driven by innovative clinical research, cutting-edge
technologies and advanced treatments, including targeted therapies
genomic-based treatment and immunotherapy. Our highest values are
embodied by our outstanding team of highly trained and dedicated
physicians, clinicians and staff.
*Prior to approval
View original content to download
multimedia:https://www.prnewswire.com/news-releases/mahdi-taha-do-facoi-facp-is-lead-author-of-case-study-demonstrating-importance-of-genomic-testing-in-early-identification-and-treatment-of-cancer-302138665.html
SOURCE Florida Cancer Specialists & Research Institute